Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026
Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1…
New employee representative on the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…
